$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000162828019002007 Filed on February 26, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018 Q3
Revenue	$21.81M	$31.34M	$22.48M
YoY Change	20.99%	34.2%	57.67%
Cost Of Revenue	$8.640M	$8.630M	$8.140M
YoY Change	12.71%	2.86%	13.28%
Gross Profit	$13.17M	$22.71M	$14.35M
YoY Change	27.11%	51.77%	102.8%
Gross Profit Margin	60.39%	72.46%	63.81%
Selling, General & Admin	$13.52M	$13.69M	$12.57M
YoY Change	23.43%	34.48%	53.54%
% of Gross Profit	102.66%	60.29%	87.61%
Research & Development	$3.008M	$3.020M	$3.113M
YoY Change	-19.33%	-15.88%	6.65%
% of Gross Profit	22.84%	13.3%	21.7%
Depreciation & Amortization	$324.0K	$300.0K	$320.0K
YoY Change	-24.12%	-28.57%	-21.95%
% of Gross Profit	2.46%	1.32%	2.23%
Operating Expenses	$16.53M	$16.71M	$15.68M
YoY Change	12.57%	21.35%	41.22%
Operating Profit	-$3.358M	$5.995M	-$1.336M
YoY Change	-22.3%	403.36%	-66.86%
Interest Expense	$2.000K	$160.0K	$460.0K
YoY Change	-99.54%	220.0%	45.11%
% of Operating Profit		2.67%
Other Income/Expense, Net	$514.0K	-$80.00K	$267.0K
YoY Change	-115.4%	-20.0%	-119.4%
Pretax Income	-$2.840M	$5.240M	-$1.070M
YoY Change	-62.92%	1706.9%	-80.22%
Income Tax
% Of Pretax Income
Net Earnings	-$2.844M	$5.242M	-$1.069M
YoY Change	-62.87%	1726.48%	-80.23%
Net Earnings / Revenue	-13.04%	16.73%	-4.75%
Basic Earnings Per Share	-$0.07	$0.12	-$0.02
Diluted Earnings Per Share	-$0.07	$0.11	-$0.02
COMMON SHARES
Basic Shares Outstanding	43.75M shares	43.35M shares	42.93M shares
Diluted Shares Outstanding			42.93M shares

Balance Sheet

Concept	2019 Q1	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.10M	$82.90M	$97.80M
YoY Change	182.21%	208.18%	530.97%
Cash & Equivalents	$35.08M	$18.29M	$53.29M
Short-Term Investments	$49.00M	$64.60M	$44.50M
Other Short-Term Assets	$2.679M	$2.847M	$2.339M
YoY Change	97.28%	80.08%	71.23%
Inventory	$4.063M	$3.558M	$3.638M
Prepaid Expenses
Receivables	$18.77M	$23.45M	$15.53M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$109.6M	$112.8M	$119.3M
YoY Change	127.38%	123.31%	228.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.445M	$5.906M	$5.207M
YoY Change	53.2%	45.07%	31.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$31.63M	$5.906M	$5.207M
YoY Change	651.79%	45.07%	31.26%
TOTAL ASSETS
Total Short-Term Assets	$109.6M	$112.8M	$119.3M
Total Long-Term Assets	$31.63M	$5.906M	$5.207M
Total Assets	$141.2M	$118.7M	$124.5M
YoY Change	169.47%	117.47%	209.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.201M	$7.108M	$4.580M
YoY Change	7.51%	28.03%	-23.31%
Accrued Expenses	$6.600M	$6.930M	$5.600M
YoY Change	873.45%	24.35%	1377.57%
Deferred Revenue			$534.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$4.100M
YoY Change	-100.0%	-100.0%	57.69%
Total Short-Term Liabilities	$12.94M	$14.79M	$14.99M
YoY Change	-6.75%	13.0%	3.19%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$0.00	$13.18M
YoY Change	-99.36%	-100.0%	78.15%
Other Long-Term Liabilities	$25.10M	$1.666M	$1.800M
YoY Change	1221.05%	-20.67%
Total Long-Term Liabilities	$25.20M	$1.666M	$13.18M
YoY Change	61.03%	-19.09%	78.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.94M	$14.79M	$14.99M
Total Long-Term Liabilities	$25.20M	$1.666M	$13.18M
Total Liabilities	$38.17M	$16.46M	$29.99M
YoY Change	21.29%	-48.63%	27.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$371.9M	-$369.0M	-$374.3M
YoY Change	0.9%	2.25%	3.62%
Common Stock	$474.8M	$471.2M	$468.4M
YoY Change	22.03%	23.02%	24.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$103.1M	$102.2M	$94.48M
YoY Change
Total Liabilities & Shareholders Equity	$141.2M	$118.7M	$124.5M
YoY Change	169.47%	117.47%	209.01%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	-$2.844M	$5.242M	-$1.069M
YoY Change	-62.87%	1726.48%	-80.23%
Depreciation, Depletion And Amortization	$324.0K	$300.0K	$320.0K
YoY Change	-24.12%	-28.57%	-21.95%
Cash From Operating Activities	$154.0K	$2.610M	$2.020M
YoY Change	-61.98%	210.71%	-138.55%
INVESTING ACTIVITIES
Capital Expenditures	$232.0K	-$580.0K	-$1.120M
YoY Change	26.09%	-19.44%	115.38%
Acquisitions	$10.69M
YoY Change
Other Investing Activities	$15.89M	-$19.87M	-$44.48M
YoY Change
Cash From Investing Activities	$15.66M	-$20.45M	-$45.60M
YoY Change	-8611.96%	2740.28%	8669.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$982.0K	-17.17M	1.910M
YoY Change	-63.55%	-252.22%	-73.44%
NET CHANGE
Cash From Operating Activities	$154.0K	2.610M	2.020M
Cash From Investing Activities	$15.66M	-20.45M	-45.60M
Cash From Financing Activities	$982.0K	-17.17M	1.910M
Net Change In Cash	$16.80M	-35.01M	-41.67M
YoY Change	476.26%	-407.11%	-3013.99%
FREE CASH FLOW
Cash From Operating Activities	$154.0K	$2.610M	$2.020M
Capital Expenditures	$232.0K	-$580.0K	-$1.120M
Free Cash Flow	-$78.00K	$3.190M	$3.140M
YoY Change	-135.29%	104.49%	-166.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	astm	Accrued Expenses Other Current AccruedExpensesOtherCurrent	491000	USD
CY2018Q4	astm	Accrued Expenses Other Current AccruedExpensesOtherCurrent	210000	USD
CY2017Q4	astm	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	8275000	USD
CY2018Q4	astm	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	9067000	USD
CY2017Q4	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	350000	USD
CY2018Q4	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	0	USD
CY2017Q4	astm	Lineof Creditand Term Loan Credit Agreement Noncurrent Netof Deferred Costs LineofCreditandTermLoanCreditAgreementNoncurrentNetofDeferredCosts	16888000	USD
CY2018Q4	astm	Lineof Creditand Term Loan Credit Agreement Noncurrent Netof Deferred Costs LineofCreditandTermLoanCreditAgreementNoncurrentNetofDeferredCosts	0	USD
CY2014Q3	astm	Operating Loss Carryforwards Limitations On Use Projected Annual Limitation On Use Of Net Operating Losses OperatingLossCarryforwardsLimitationsOnUseProjectedAnnualLimitationOnUseOfNetOperatingLosses	800000	USD
CY2018Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDue	18352000	USD
CY2018Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Current OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueCurrent	5661000	USD
CY2018Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Four Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInFourYears	1642000	USD
CY2018Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Three Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInThreeYears	5469000	USD
CY2018Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Two Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInTwoYears	5471000	USD
CY2018Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Thereafter OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueThereafter	0	USD
CY2018Q4	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Duein Five Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueinFiveYears	109000	USD
CY2016	astm	Other Revenue OtherRevenue	0	USD
CY2017	astm	Other Revenue OtherRevenue	1164000	USD
CY2018	astm	Other Revenue OtherRevenue	0	USD
CY2015Q4	astm	Purchase Obligation Automatic Renewal Term PurchaseObligationAutomaticRenewalTerm	P5Y
CY2015Q4	astm	Purchase Obligation Renewal Option Term PurchaseObligationRenewalOptionTerm	P5Y
CY2017	astm	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	4010000	USD
CY2018	astm	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	6255000	USD
CY2017Q4	astm	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	11700000	USD
CY2016	astm	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	0	USD
CY2017	astm	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	0	USD
CY2018	astm	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	3538000	USD
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43753005	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	412774169	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5552000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7108000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18270000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23454000	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	327000	USD
CY2017Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2693000	USD
CY2018Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5161000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5573000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6930000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6621000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7505000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-39000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2499000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2680000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7223000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1653000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	311000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4700	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	190000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	207000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	249000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	514000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5300000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5400000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4800000	shares
CY2017Q4	us-gaap	Assets Assets	54577000	USD
CY2018Q4	us-gaap	Assets Assets	118689000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	50506000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	112783000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	39000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	75515000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	75476000	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	341000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	606000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	205000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	41000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	41000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	41000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	41000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	41000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q4	us-gaap	Cash Cash	14581000	USD
CY2016Q4	us-gaap	Cash Cash	22978000	USD
CY2017Q4	us-gaap	Cash Cash	26862000	USD
CY2018Q4	us-gaap	Cash Cash	18286000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35861000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43578000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35861000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43578000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	383020000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	471180000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19566000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17286000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8176000	USD
CY2017Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	0	shares
CY2016	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28307000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	30354000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32160000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	67000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	0	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	196000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1900000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	420000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	566000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24248000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25936000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2568000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2339000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10487000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10969000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	282000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	345000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	508000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	418000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2128000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2798000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24248000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25936000	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2016	us-gaap	Depreciation Depreciation	1600000	USD
CY2017	us-gaap	Depreciation Depreciation	1600000	USD
CY2018	us-gaap	Depreciation Depreciation	1400000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1886000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1612000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1426000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1014000	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2389000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1559000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	257000	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2524000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-5000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-37000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-51000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	115000	USD
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-22000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-860000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-838000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	14961000	USD
CY2016	us-gaap	Gross Profit GrossProfit	26076000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	2252000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	9283000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	7074000	USD
CY2017	us-gaap	Gross Profit GrossProfit	33570000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	10361000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	11284000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	14346000	USD
CY2018Q4	us-gaap	Gross Profit GrossProfit	22706000	USD
CY2018	us-gaap	Gross Profit GrossProfit	58697000	USD
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2638000	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2016Q1	us-gaap	Incentive From Lessor IncentiveFromLessor	2000000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19566000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17286000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8137000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7677000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5445000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1688000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-614000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	11749000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	839000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6652000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5877000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1709000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	549000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	563000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-605000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	56000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	116000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	172000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1016000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1106000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-385000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	100000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1076000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1361000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	899000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	920000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1050000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1493000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2108000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	305000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-235000	USD
CY2016	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	701000	USD
CY2017	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	261000	USD
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1267000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	217000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	41000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	39000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-1568000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-785000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	247000	USD
CY2016	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	6174000	USD
CY2017	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1177000	USD
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	5184000	USD
CY2016	us-gaap	Interest Expense InterestExpense	15000	USD
CY2017	us-gaap	Interest Expense InterestExpense	92000	USD
CY2018	us-gaap	Interest Expense InterestExpense	31000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	226000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	931000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2230000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	48000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	3793000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3558000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3532000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2872000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	226000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	638000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	897000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	32037000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	16458000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54577000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118689000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13090000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14792000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2059000	USD
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1666000	USD
CY2016	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	8397000	USD
CY2017	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3884000	USD
CY2018	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-8576000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29704000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18577000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58863000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1415000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1510000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67027000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19892000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13183000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-412000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	287000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-19566000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-9778000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2388000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5407000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-17286000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-7659000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-4651000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1069000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	5242000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-8137000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27145000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17286000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8137000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-321000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2302000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4228000	USD
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016	us-gaap	Operating Expenses OperatingExpenses	45321000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	48554000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	62606000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1191000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-19245000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9623000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2521000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4031000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-14984000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4322000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4246000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1336000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	5995000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-3909000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	15386000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4879000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	68000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	966000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4754000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4719000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4800000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5600000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5500000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1581000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2847000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-39000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	181000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	188000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-314000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1107000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1732000	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	583000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	710000	USD
CY2016	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	213000	USD
CY2017	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	30000	USD
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1415000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1510000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2678000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	66549000	USD
CY2016	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7579000	USD
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2018	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	70028000	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	190000	USD
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	207000	USD
CY2018	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	19455000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8220000	USD
CY2018	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4361000	USD
CY2016	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	2200000	USD
CY2016	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	12710000	USD
CY2017	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	14793000	USD
CY2018	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	0	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4010000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2716000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10692000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13411000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4071000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5906000	USD
CY2018Q4	us-gaap	Purchase Obligation PurchaseObligation	2761000	USD
CY2018Q4	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	635000	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	741000	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	711000	USD
CY2015Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	600000	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	674000	USD
CY2016	us-gaap	Repayments Of Debt RepaymentsOfDebt	38000	USD
CY2017	us-gaap	Repayments Of Debt RepaymentsOfDebt	7151000	USD
CY2018	us-gaap	Repayments Of Debt RepaymentsOfDebt	17532000	USD
CY2016	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2400000	USD
CY2017	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	889000	USD
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15295000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12944000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13599000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-360877000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-369000000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-369014000	USD
CY2016	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54383000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62760000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90857000	USD
CY2016Q4	us-gaap	Revenues Revenues	23350000	USD
CY2016	us-gaap	Revenues Revenues	54383000	USD
CY2017Q1	us-gaap	Revenues Revenues	9361000	USD
CY2017Q2	us-gaap	Revenues Revenues	16953000	USD
CY2017Q3	us-gaap	Revenues Revenues	14260000	USD
CY2017	us-gaap	Revenues Revenues	63924000	USD
CY2018Q1	us-gaap	Revenues Revenues	18027000	USD
CY2018Q2	us-gaap	Revenues Revenues	19011000	USD
CY2018Q3	us-gaap	Revenues Revenues	22484000	USD
CY2018Q4	us-gaap	Revenues Revenues	31335000	USD
CY2018	us-gaap	Revenues Revenues	90857000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27388000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35610000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	49007000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2499000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2680000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	7223000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	64638000	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	3150000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	38389000	USD
CY2018	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	467000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	425000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	656000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18868000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7188000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70028000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	120000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	608000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3705000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	22130000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	24708000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	22540000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	102231000	USD
CY2018	us-gaap	Unrealized Loss On Securities UnrealizedLossOnSecurities	39000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1700000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	397000	USD
CY2018Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	104000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23093000	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33355000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40242000	shares
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">société anonyme</font><font style="font-family:inherit;font-size:10pt;"> (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and a portfolio of patents and patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), related to the MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company and currently markets MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> in the U.S. The Company is a leader in advanced cell therapies for the sports medicine and severe burn care markets. MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults that was approved by the FDA on December 13, 2016. The first shipment and implantation of MACI occurred on January 31, 2017. At the end of the second quarter of 2017, the Company removed Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (autologous cultured chondrocytes), an earlier generation ACI product, from the market. The Company also markets Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (cultured epidermal autografts), a permanent skin replacement Humanitarian Use Device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (TBSA). The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  As of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the Company has an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$369.0 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> and had a net loss of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> during 2018.  The Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$18.3 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> and short term investments of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$64.6</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> million as of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#222222;">. On December 19, 2018, the Company terminated and prepaid in full all outstanding indebtedness under the Loan and Security Agreement dated as of September 9, 2016 as amended, by and between the Company, Silicon Valley Bank as Agent and Silicon Valley Bank, MidCap Financial Trust, MidCap Funding III Trust (SVB and MidCap) and other lenders listed therein as lenders (SVB Loan Agreement). The Company expects that existing cash, cash equivalents and short term investments will be sufficient to support the Company's </font><font style="font-family:inherit;font-size:10pt;">current operations through at least February 2020.</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> The Company may seek additional funding through debt or equity financings.  However, the Company may not be able to obtain financing on acceptable terms or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's shareholders.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-002007-index-headers.html	Edgar Link	pending
0001628280-19-002007-index.html	Edgar Link	pending
0001628280-19-002007.txt	Edgar Link	pending
0001628280-19-002007-xbrl.zip	Edgar Link	pending
a2018stockchart.jpg	Edgar Link	pending
astm-20181231.xml	Edgar Link	completed
astm-20181231.xsd	Edgar Link	pending
astm-20181231_cal.xml	Edgar Link	unprocessable
astm-20181231_def.xml	Edgar Link	unprocessable
astm-20181231_lab.xml	Edgar Link	unprocessable
astm-20181231_pre.xml	Edgar Link	unprocessable
ex1048formofnewhireisoagre.htm	Edgar Link	pending
ex1049formofisoagreement20.htm	Edgar Link	pending
ex1050formofnonemployeeiso.htm	Edgar Link	pending
ex1051formofrsuawardagreem.htm	Edgar Link	pending
ex211subsidiariesofregistr.htm	Edgar Link	pending
ex231consentofregisteredin.htm	Edgar Link	pending
ex311certificationq42018.htm	Edgar Link	pending
ex312certificationq42018.htm	Edgar Link	pending
ex321certificationq42018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vcel12-31x201810k.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2019 Q1 Form 10-K Financial Statement

#000162828019002007 Filed on February 26, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2019 Q1 Form 10-K Financial Statement

#000162828019002007 Filed on February 26, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel